Abstract

Around 2.5 million people worldwide have multiple sclerosis, of whom about 85,000 are in the UK.1 ▼Natalizumab (pronounced na-ta-liz-you-mab; Tysabri – Biogen Idec), the first in a new class known as selective adhesion-molecule inhibitors, is licensed in the UK as monotherapy for “highly active” relapsing/remitting multiple sclerosis.2 Here we review natalizumab and assess its place for patients with multiple sclerosis.